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Diabetes has recently become a leading cause of death worldwide. To date, although there
is no means to cure or prevent diabetes, appropriate medication and blood sugar moni-
toring can enhance treatment efficiency, alleviate the symptoms, and diminish the com-
plications of the condition. This review article deals with current growth areas in the
market for blood glucose sensors and possible future alternatives, which are generally
considered to be the point sample test and the continuous glucose monitor (CGM). Most
glucose sensors are enzyme-based, whereas others are enzyme-free. The former class is
sensitive and some products are extensively employed for daily self-sensing and in hos-
pital environments as reliable diagnostic tools. The latter class, particularly the boronic
acid fluorescent sensor, is facile and extremely promising. Practicality demands that all
types of sensors offer accuracy, specificity, and real-time detection.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Since Emil Fischer established the monumental theory of su-
pramolecular chemistry on interactions between substrate
molecules and specific enzymes, molecule recognition is of
particular interest to numerous scientists [1]. Molecular
recognition based on the lock-and-key principal occurs in
biological systems such as enzymeesubstrate interactions,
antigen evoking antibody [2e5], and sugar binding to lectin
[6e9]. Following development of the first two-dimensional
structure of crown ether for a specific metal ion by Pedersen,
Cram, and Lehn [10], the possibility of synthetic receptors that
mimic important biological activities was demonstrated.
Particularly, saccharide recognition attracts the attention of, National Defense Medic
.-R. Lee).
ministration, Taiwan. Publbiochemists and medicinal chemists not only because sac-
charides are involved in cellecell interactions within biolog-
ical organisms but also because saccharide sensing offers
promise for clinical diagnostic applications such as blood
sugar level, pathogens, and cancer [11e18].2. Saccharides and their importance
Carbohydrates, the most abundant organic form of material
on the earth, which form biological building blocks and di-
etary components, are classified as single sugars (mono-
saccharides) and their polymers, namely oligosaccharides and
polysaccharides [19e21].al Center, 9F, Number 161, Section 6, Minchun East Road, Taipei
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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basic of carbohydrates, serving both as energy fuels and
fundamental constituents of living organisms. For example,
five-carbon sugars exist in information carriers, such as
deoxyribose in DNA and ribose in RNA; moreover, the best-
known six-carbon sugars include D-glucose, also known as
either grape sugar or blood sugar; D-fructose, fruit sugar; and
D-galactose, which forms milk sugar when combined with
glucose. The D series of sugars are thus designated based on
the observation that most natural monosaccharides have the
same configuration at C-5 as D-glyceraldehyde. In aqueous
solution, the isomeric structures of glucose molecules display
equilibrium. In neutral solution, glucose exhibits the linear
open-chained form in <0.1% of molecules. Most of these
molecules exist as a more stable cyclic hemiacetal with a six-
membered pyran ring and thus are termed the pyranose
(Fig. 1).
In humans, D-glucose is vital for its role in metabolic ho-
meostasis; it acts as an energy source in living systems and
maintains human bodily functioning when consumed or
through the formation of other essential saccharides via
biosynthesis. When taken up by human cells, glucose can be
either broken down (glycolysis) to yield energy, converted into
other metabolites in the form of metabolic intermediates, or
polymerized to form cellulose and starch through biosyn-
thesis to function properly. In the human body, besides
existing in free form, glucose can covalently link to lipids
(glycolipids) and proteins (glycoproteins) and other biological
molecules as glycoconjugates, which are crucial building
components of cell membranes and are mainly involved in
the mechanism of intercellular recognition [22].
Monosaccharides can also join other sugars via glycosidic
bonds through the sequential reaction of their anomeric hy-
droxyl groups with the hydroxyl groups of other sugars,
together with the elimination of water, resulting in a yield of
oligosaccharides or polysaccharides. The simplest and most
biologically important oligosaccharides are disaccharides.
Three naturally abundant disaccharides are maltose, lactose,
and sucrose. The glycosidic linkages of these three di-
saccharides are formed stereospecifically by enzymes; there-
fore, only one of the possible configurations (a or b) occurs
and, like all glycosides, its mutarotation is not permitted.
Maltose, which occurs mainly in malt, comprises two D-
glucose units joined with an a(1/4) bond via a condensation
reaction. Lactose, the most important sugar in mammalian
milk, is the combination of D-galactose and D-glucose. Su-
crose, also named table sugar, consists of D-glucose and D-
fructose. Oligosaccharides also form glycoconjugates with
proteins and lipids, some of which are important in cell
biology. Additionally, taking advantage of their biological ef-
fects, complex oligosaccharides and their analogs are widelyO
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Fig. 1 e Linear and cyclic form of D-glucose.applied in pharmaceuticals. For example, the first oligosac-
charide analog used as a chemotherapeutic agent was strep-
tomycin, a bactericidal aminoglycoside antibiotic isolated in
1943, and also the first cure for tuberculosis. Acarbose, an
antidiabetic drug used to treat type II diabetic mellitus by
inhibiting a-glucosidase, localized in the brush border of in-
testinal epithelium, is also an oligosaccharide derivative
comprising two glucosemoieties with a rare sugar unit. Cyclic
oligosaccharides such as cyclodextrins, obtainable by partial
hydrolysis of starch, which bear a hydrophilic exterior and
hydrophobic interior, can form hosteguest complexes and be
applied in drug delivery systems (Fig. 2) [21]. Cyclodextrins
also have numerous applications in foods, pharmaceuticals,
chemicals, and agriculture.
Polysaccharides, macromolecules comprising numerous
monosaccharide moieties, are ubiquitous in nature. They are
frequently classified into three classes according to function:
structural polysaccharides, water-binding polysaccharides,
and reserve polysaccharides. Polysaccharides are important
biological polymers and possess great structural diversity.3. Glucose-related disease: diabetes
Various saccharides-related diseases are common in clinical
practice, including disorders of carbohydrate metabolism,
such as lactose intolerance, Andersen's disease, Pompe dis-
ease (acid maltase deficiency) [23,24], obesity, hypoglycemia,
hyperactivity (mostly in children), and most important of all,
diabetes [25e27].
Diabetes is a chronic disease that has devastating human,
social, and economic consequences. According to the World
Health Organization (WHO) and the International Diabetes
Federation, its worldwide prevalence is projected to double
over the next couple of decades, from 347 million people in
2005 to 700 million people in 2030. Notably, >80% of diabetic
patients live in low- and middle-income countries [25,28].
Diabetes can be divided into three main types. Type I dia-
betes is insulin-dependent; it was previously called insulin-
dependent diabetes mellitus or juvenile diabetes. It is caused
by deficient insulin production within the body and typically
manifests among the youth. Daily replacement of insulin be-
comes indispensable for those with the condition. Type II
diabetes is noninsulin-dependent and is caused by insulin
resistance, a condition in which the target organs develop a
failure to properly respond to insulin. Type II diabetes is
termed adult-onset diabetes and makes up >95% of all cases.
Gestational diabetes occurs when pregnant women, usually
without a previous history of diabetes, develop a high blood
glucose level. Womenwith gestational diabetes typically have
a high risk of eventually developing type II diabetes.
Although diabetes is not actually caused by saccharides, it
is one of the most notorious saccharide-related diseases. This
is because body cells cannot digest glucose from blood
themselves. To maintain blood sugar concentration following
ingesting carbohydrate, the body requires insulin, produced
and released from the B- (or b-) cells of the pancreas, to
transport glucose into cells for subsequent metabolism. The
result of inefficient insulin production or secretion is an
excessive rise in blood glucose, even spilling into the urine.
Fig. 2 e Common oligosaccharides and their analogs.
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has also warned that the number of deaths from diabetes is
expected to increase by >50% over the next decade. Nowa-
days, one person dies from diabetes every 10 seconds. Dia-
betes has become an urgent global problem that requires
serious action.4. Glucose sensors
Despite the lack of any known cure for diabetes, we have
managed to improve treatment efficiency to alleviate its
symptoms and diminish its complications through appro-
priate medication and blood sugar monitoring, to improve
treatment decisions and glucose control. Glucose sensor sys-
tems are classified into two groups based on duration of
measurementmethod and time: the point sample test and the
continuous glucose monitor (CGM) (Table 1) [29]. Most glucose
sensors are enzyme-based, whereas others are enzyme-free.4.1. Point sample test
The earliest method for glucose detection was based on the
formation of a Schiff base (imine) between aldehydes and
aromatic amines. The reaction of the aldehyde group on
glucosewith 2-methylaniline (o-toluidine) forms a stable blue/
green color imine (an anil). The resulting imine displays a
maximum absorption (lmax) in the visible region of the spec-
trum at 625 nm (Scheme 1). The glucose concentration is
proportional to the absorption intensity. The glucose con-
centration in the test sample can be obtained based on the
plot of a standard curve. Themain weakness of this method is
its lack of selectivity owing to aldehyde being the common
functional group in numerous sugars and consequent preva-
lence of false-positive results. Fortunately, glucose is the
principal saccharide in the blood; other monosaccharides and
disaccharides are present only in very low concentrations.
By exploiting glucose oxidase as an enzyme specific to b-D-
glucose, an enzyme-based assay was introduced to assess
Table 1 e Technologies under development for glucose sensors [29].
Glucose sensor Point sample Urine dipstick
Finger prick glucometer
Continuous Invasive Subcutaneous amperometric electrodes, microdialysis, intravenous
implantable devices, and micropores/microneedles
Noninvasive Transdermal: reverse iontophoresis, sonophoresis, etc
Optical: fluorescence, infrared spectroscopy, Raman spectroscopy, etc
Scheme 1 e Reaction of D-glucose and o-toluidine.
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glucose oxidase, readily oxidizes b-D-glucose to D-gluconic
acid, while it is reduced to hydrogen peroxide (H2O2). The
generated H2O2 can then further oxidize o-toluidine to form a
colored product with a concentration proportional to that of
H2O2 and hence to that of glucose. Based on this concept,
several commercial test kits have been employed as routine
diagnostic tools, including those utilizing chemical strips, and
those used to test blood and urine glucose levels by sampling
specimens directly into the strip followed by visual reading of
the color charts (Scheme 2).
In 1971, Clemens developed the Ames Reflectance Meter
(ARM), a device to detect reflected light and automatically
assess strip color change, using a standard strip for calibra-
tion. The ARM was also the first blood glucose monitor patent
filed in the USA for point-of-care test devices for diabetes
patients [29].
Existing point sample tests require patients to draw blood
with a lancet several times daily. Such discrete tests are un-
suited for use while sleeping or driving, and moreover hyper-
or hypoglycemia events are unlikely during sampling.
4.2. CGM
Investigations have demonstrated that intensive glycemic
control to maintain blood sugar levels as near normal (eugly-
cemia) as possible can diminish complications of diabetes and
improve quality of life, stimulating the launch of numerous
investigations on CGMs. CGM systems employ a tiny sensor
inserted beneath the skin and remain in place for a period of
time to assess glucose levels in tissue fluid. CGM systems
should provide data on glucose levels, particularly the ten-
dency, magnitude, frequency, period, and changes of fluctu-
ations in real-time to alarm patients should rapid changes in
glucose levels occur in the blood, particularlywhile sleeping or
exercising. Numerous technologies are involved in CGM in-
vestigations, and they can be classified as invasive and
noninvasive (Table 1).4.2.1. Invasive continuous glucose sensors
In 1954, the first oxygen electrode, known as the “Clark elec-
trode”, was invented by the American biochemist Leland C.
Clark, also considered the “Father of Biosensors” [30]. To
monitor oxygen signals and calibrate the oxygen electrode,
Clark used glucose and a glucose-specific enzyme, glucose
oxidase, to remove oxygen by reducing it to H2O2. This process
found the decrease of oxygen to be proportional to the con-
centration of glucose in the solution. Eventually, Clark real-
ized that this simple device could be used to measure oxygen/
glucose in water, blood, and other solutions. Most modern
glucose sensors used daily by millions of diabetics are based
on Clark's concept.
Invasive continuous glucose sensor research involves four
technologies: subcutaneous amperometric electrodes, micro-
dialysis, intravenous implantable devices, and micropores/
microneedles. To date, only subcutaneous and microdialysis
studies have yielded commercial products. Subcutaneous
needle-type sensors adapt protected technologies, and
immobilize enzyme and mediator onto a polymer membrane
and electrode surface. Glucose oxidase serves as the catalyst
to convert glucose to gluconolactone. Reductioneoxidation
reactions can generate a concentration-dependent current or
voltage to be measured by electrochemistry (Fig. 3) [29,31].
In 1990, the Medtronic MiniMed (Northridge, CA, USA)
introduced the Continuous Glucose Monitor System (CGMS),
the first CGM approved by the US Food and Drug Administra-
tion (FDA). The CGMS allows 3-day continuous glucose moni-
toring and data recording, where blood glucose measurement
records can be processed and analyzed retrospectively. Cur-
rent Medtronic products are the Guardian REAL-Time and
MiniMedParadigmReal-Time (glucosemonitor combinedwith
insulin pump). In 2006, the first real-time continuous glucose
monitoring system, DexCom-7, was approved by the FDA and
in 2007 its lifetime was extended from 3 days to 7 days. The
latest CGMSmodel to follow this FreeStyle Navigator achieved
5 days of continuous glucosemonitoring andwas approved by
the FDA in 2008 (Table 2) [32e34].
Fig. 3 e Enzyme-based electrode with glucose oxidase and mediators [29,31].
Scheme 2 e Oxidation of D-glucose catalyzed by glucose oxidase.
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for glucose trend analyses, use a subcutaneous inserted
hollow fiber combined with a semipermeable membrane
filter. The membrane is permeable to glucose and other
small molecules. Meanwhile, the fiber is perfused with
isotonic fluid, glucose in the interstitial fluid diffuses into
the fiber, and the fluid is then pumped to an enzyme-based
electrode. The glucose concentration depends on the equi-
librium of the interstitial fluid. A common weakness of this
technology is membrane blockage owing to biofouling.
GlucoDay (Menarini Diagnostics, Firenze, Italy), marketed in
2002, is the only commercial product approved in Europe
[32].
Consequently, the first generation of invasive CGMs are all
enzyme-based sensors and require calibration using the
finger-prick blood sensor. Future improvement in invasive
CGMs will undoubtedly focus on accuracy, reliability, cost,
and lifetime.Table 2 e Comparison of current market CGMS devices [33,34]
Brand Guardian Real-Time MiniMed 530G wi
Company Medtronic Medtronic
FDA approved date 2006 2007
Sensor life (d) 3 6
Sensor style Insertion under skin Insertion under ski
Startup initialization
time (h)
2 2
Calibration (Y/N)
with finger-stick test
Y, 2 h after insertion,
and the first 6 h, then
every 12 h
Y, 2 h after insertio
the first 6 h, then e
CGMS ¼ continuous glucose monitor system; FDA ¼ Food and Drug Adm4.2.2. Noninvasive continuous glucose sensors
The availability of home-use glucometers has significantly
improved quality of life for diabetes sufferers; however, such
monitors require a new strip for each test, as well as a blood
draw from the finger pricks, with the latter causing pain and
inconvenience. To overcome the short lifetime and calibration
needs of the invasive continuous glucose system, and to in-
crease patient compliance, noninvasive continuous glucose
sensors represent an obvious solution. Numerous technolo-
gies pursued as noninvasive sensor systems can be classified
as transdermal and optical sensors [33,34].
4.2.2.1. Transdermal sensors. GlucoWatch (Cygnus Inc., Red-
wood City, CA, USA), a transdermal noninvasive continuous
glucose sensor approved by the FDA in 2001, is worn on the
wrist like a watch and does not require drawing blood. Glu-
coWatch employs reverse iontophoresis. A patented hydrogel
pad is located between the skin and an electrode. A small.
th Enlite Dexcon G4 Platinum FreeStyle
Dexcom Abbott
2007 2008
7 5
n Insertion under skin Insertion under skin
2 10
n, and
very 12 h
Y, every 12 h Y, approximately 1, 2, 10, 24,
and 72 h after insertion
inistration.
Fig. 4 e Principle of fluorescence resonance energy transfer (FRET) from Concanavalin A (Con A) to dextran by adding
glucose [36].
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draws out interstitial fluid from the skin to the iontophoretic
electrode. The glucose concentration in the sampling fluid is
1000 times lower than that of interstitial fluid below the skin
(the concentration of glucose in the interstitial fluid can
sometimes be 100 times greater than the oxygen concentra-
tion) and is detected using the glucose oxidase catalytic sys-
tem. Low glucose concentration means oxygen supply ceases
to be a limitation for glucose oxidase. Additionally, the skin
filters off large molecules, reducing biofouling and electro-
chemically active fouling. However, the extended warm-up
time, difficult operation, need for calibration, and most
importantly, skin irritation, are all disadvantages of this
technology. Consequently, GlucoWatch was withdrawn from
the market after 2008.
Compared to transdermal technology, alternative optical
technology offers more investigative options, including
polarimetry, Raman spectroscopy, scattering/occlusion spec-
troscopy, (near) infrared spectroscopy, fluorescence, photo-
acoustic spectroscopy, optical coherence tomography, etc.
To date, the medical market lacks a product for optical
continuous glucose monitoring. However, owing to the prev-
alence of diabetes, optical technology has attracted increasing
scientific attention. Among all types of glucose sensors, fluo-
rescence is considered the most promising technology for
creating the ideal glucose sensor.
4.2.2.2. Optical sensors: fluorescence-based glucose sensors.
Fluorescence is a specific type of photoluminescence. When aScheme 3 e Reaction of glucose oxidation with flavin adenine d
oxidation of FAD [22].molecule with a rigid structure absorbs light energy from the
ground state to an excited state, it returns to the ground state
by emission of light, at a lower energy level than that at which
it absorbed light, from different singlet states and is known as
fluorescence. Fluorescence-based technology possesses
numerous advantages over the conventional ultraviolet-
visible spectrophotometry used in sensing. Fluorescence
spectrophotometry is extremely sensitive and causes only
trivial damage to the host. Fluorescence can be measured not
only by its intensity but also its lifetime (generally <105 s).
Fluorescence spectrophotometry also offers information on
biomolecule structure and environment and how bio-
molecules respond and change in healthy versus diseased
states [35].
The Concanavalin A (Con A) sensor developed in 1984 was
the first fluorescence-based glucose sensor. Con A is a plant
lectin (carbohydrate-binding protein) and a homotetramer,
with each possessing a specific glucose binding site. Con A can
be labeled using a fluorophore (fluorescein isothiocyanate or
allophycocyanin, as the fluorescent donor) and immobilized
to fine, hollow fibers. Dextran, another polysaccharide, is also
labeled with a fluorophore (rodamine or malachite green, as
the fluorescent receptor) in the fiber. Glucose and dextran are
competing ligands of Con A in the fiber system. The combi-
nation of dextran with Con A causes fluorescence resonance
energy transfer (FRET) from the fluorescence donor to the
fluorescent receptor. Addition of further glucose replaces
more dextran, and consequently a corresponding decrease in
FRET (Fig. 4) [29,36].inucleotideeglucose oxidase (FAD-GOx) and reversible
Scheme 4 e D-Glucose catalyzed by hexokinase forms D-glucose-6-phosphate.
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fluorescein, enabling energy transfer from intrinsic flavin
adenine dinucleotide fluorescence of glucose oxidase to the
extrinsic fluorophore. In this system, glucose concentration is
not proportional to the fluorescence intensity, but rather to
the time between the addition and the fluorescence change
(Scheme 3) [22].
D-Glucose canbe subjected to phosphorylation, catalyzedby
a hexokinase (glucokinase), to D-glucose-6-phosphate coupling
with the hydrolysis of adenosine-50-triphosphate (ATP). Hexo-
kinase from yeast usually exists as a dimer and has intrinsic
fluorescence that is quenched following adding glucose. How-
ever, hexokinase is temperature-unstable, which limits its
application (Scheme 4) [22].
4.3. Newcomers: enzyme-free boronic acid-based glucose
sensors
The above mentioned glucose sensors on the current medical
diagnosis market are mostly enzyme-based sensors, such as
glucose oxidase or glucose dehydrogenase, and rely on elec-
trochemical analytical measurement. However, the good
sensitivity of enzyme-based glucose sensors is counteracted
by instabilities due to numerous other factors such as envi-
ronmental temperature and pH. The biological foil can alsoScheme 5 e Interaction of phenylboronic with 1,2- acause sensor instability and false alarms, as well as missed
blood glucose readings [37]. Numerous efforts have beenmade
on the development of enzyme-less or enzyme-free glucose
sensors involving nanostructured electrodes to oxidize
glucose directly on the surface. However, chloride fouling
following a long detection period remains problematic
[38e44]. Another alternative method for enzyme-free glucose
sensors is synthetic boronic acid-based receptors [31,45].
A boronic acid is a substituted boric acid containing a
carbon (C)eboron (B) bond that belongs to the larger class of
organoboranes and serves as a Lewis acid capable of reacting
with Lewis bases, such as cis-1,2-diol and cis-1,3-diols or
amino acids, to form reversible covalent complexes of five-
and six-membered cyclic boronate esters. During the last
decade, numerous boronic acid-based fluorescent sensors
have developed as saccharide sensors and some specific bis-
boronic acid sensors even reveal high selectivity for D-glucose
(Scheme 5) [35,46,47].
Boronic acidesugar recognition can be explained by the
nitrogen (N)eB interaction and the photoinduced energy
transfer (PET) mechanism [31]. The NeB interaction is some-
times considered a hydrogen bond-like interaction. However,
in protic solvent systems, solvent insertion can occur in NeB
interaction to generate a zwitterionic species. Moreover, in
protic media, the NeB interaction can better be described bynd 1,3-diols to form cyclic boronate esters [46].
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interaction in protic solvent systems is indirect, it remains an
important effect in sensory systemdesignand application [48].
Regarding the NeB interaction, the PET mechanism was
introduced to the design of boronic acid fluorescent sensors.
Initially, itwas proposed that a reduction of boronic acid pKa via
the NeB interaction facilitates binding of the saccharides and
boronic acid at physiological pH 7.4. Later, when a 1,2- or 1,3-
diol binds with a boronic acid, it rapidly but reversibly forms a
cyclic boronate ester, increasing the Lewis acidity of boron, as
well as the NeB interaction. Given these advantages, the NeB
interaction can helpmodulate the neighboring fluorophore and
create a fluorescence offeon response in the sensory system.
The first fluorescence PET sensor was described by James
et al [49] in 1994 and has recently experienced strong growth.
Notably, the anthracene-based N-methyl-o-(aminomethyl)
phenylboronic acid (3) was selective for increase of D-fructose
and fluorescent intensity on addition of saccharides. TheFig. 7 e Schematic representation of the Fluorophore-Spacer-Re
energy transfer (PET) sensory system [50].selectivity for D-glucose can be improved by introducing a
second boronic acid, for example, (4), to the system (Fig. 6) [50].
A fluorophore-spacer-receptor model can clearly describe the
fluorescence off-onmechanism of the PET sensor (Fig. 7) [50]. In
this model, in the neutral boronic acid state (sugar-free), the
electrons (in most cases from the nitrogen) can be internally
transferred to the fluorophore and cause fluorescence quench-
ing to create the sensor off spate. Once the boronic acid binds
witha sugar, the increasedLewisacidity of theboronateattracts
the electron fromnitrogen, then bindswith the boron atomand
creates a sensor on state, which enhances fluorescent intensity.
Besides fluorescence analysis, electrochemical impedance
spectroscopy and surface plasmon resonance were also
administered in boronic acid-based glucose sensors (Fig. 8)
[37,51].ceptor design assembly for fluorescence photoinduced
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in the application of boronic acid sensors [52]. These contact
lenses using acrylamide copolymer hydrogel with phenyl-
boronic acid incorporate new monosaccharide fluorescent
signaling boronic acid-containing probes and enable the
measurement of lachrymal glucose concentration [53]. When
the boronic acid copolymer binds with glucose, the interfer-
ence fringes swell and alter the color of the light reflected by
the holographic element of the contact lens. This color change
occurs proportionally to the glucose concentration. The probe
technology can employ fluorescence, fluorescence lifetime,
colorimetric, or polarization-based methods.
Despite extensive research on enzyme-free glucose sen-
sors, the clinical market has no commercial products. Mean-
while, improvements in biocompatible sol-gel, potential
fluorescence lifetime tests, the application of quantum dots
for size-dependent fluorescence emission, and the design of
highly selective boronic acid derivatives are expected to
continue.5. Conclusion
Givendemand fromthegrowingglobal populationof diabetics,
the development of blood glucose control and monitoring
technology has achieved significant progress over the past
decade.This reviewsummarized currentgrowthareas inblood
glucose sensors, ranging from invasive to noninvasive devices.
Compared with point of sample tests, CGMS offers diabetes
patients a means of real-time measurement of blood glucose
level together with alarms of blood glucose events, thus
improving their quality of life. However, limitations of sensor
lifetime and the accuracy of CGMS still require constant cali-
bration against point of sample tests. Boronic acid derivatives
offer promising alternatives as enzyme-free-based glucose
sensors, althoughmany such applications remain immature.Conflicts of interest
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